Log in  First Connection?
  
EnglishJapaneseFrenchSpanishGerman

Blood CancerArchives

Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial
Blood Cancer
 1 min.

 Published on 23/06/2026 |  Original article (Full-text)  | Mina, Roberto et al. | Journal of Patient-Reported Outcomes. Volume 10(1).

The Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) is a validated, disease-specific patient-reported outcome (PRO) instrument that measures symptoms and impacts experienced by patients with multiple myeloma (MM). We describe key measurement properties of the MySIm-Q instrument using CARTITUDE-4...

HTML version PDF version  Print abstract

Anti-CD123 monoclonal antibodies as therapeutic agents for acute myeloid leukemia: a systematic review
Blood Cancer
 1 min.

 Published on 16/06/2026 |  Original article (Full-text)  | Vitória Maria Vito et al. | Expert Review of Hematology 2026; aop:10.1080/17474086.2026.2685775

Acute myeloid leukemia is a hematological malignancy characterized by clonal expansion and blockade of myeloid precursor differentiation. This results in poor survival rates, particularly among older patients and those with refractory disease. CD123, the α-chain of the interleukin-3 receptor, is...

HTML version PDF version  Print abstract

Sexual health and intimacy concerns among patients with chronic lymphocytic leukemia: a cross-sectional needs assessment study
Blood Cancer
 1 min.

 Published on 09/06/2026 |  Original article (Full-text)  | Ilana Levy Yurkovski et al. | Leukemia & Lymphoma 2026; aop:10.1080/10428194.2026.2682282

Sexual health is an important component of survivorship, yet data specific to chronic lymphocytic leukemia (CLL) are limited. We aimed to characterize self-reported sexual health concerns and supportive care needs among adults with CLL. In this cross-sectional anonymous survey, adults with CLL completed...

HTML version PDF version  Print abstract

Plasma proteome profiles of standard-risk and high-risk childhood acute lymphoblastic leukemia
Blood Cancer
 1 min.

 Published on 02/06/2026 |  Original article (Full-text)  | Najia Tabassum et al. | Expert Review of Proteomics 2026; aop:10.1080/14789450.2026.2676596

This exploratory study aimed to characterize plasma proteome profiles across different risk groups and investigate underlying molecular mechanisms using bioinformatics approaches. This is a case-control study. Plasma samples from 15 children per group- standard-risk B-ALL (B-ALL SR), high-risk B-ALL...

HTML version PDF version  Print abstract

Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan
Blood Cancer
 1 min.

 Published on 26/05/2026 |  Original article (Full-text)  | Yuki Goshima a b et al. | Leukemia & Lymphoma 2026; aop:10.1080/10428194.2026.2665793

Venetoclax (VEN)-based regimens are widely used for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, but VEN dosing patterns and their relation to treatment persistence are not well described. We conducted a retrospective longitudinal study using de-identified...

HTML version PDF version  Print abstract